Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction

Fujisaka, Tomohiro; Fujita, Shuichi; Maeda, Daichi; Shibata, Kensaku; Takahashi, Hideaki; Morita, Hideaki; Takeda, Yoshihiro; Ito, Takahide; Sohmiya, Koichi; Hoshiga, Masaaki; Ishizaka, Nobukazu

doi:10.1007/s00380-017-1002-7

Cited by 9 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also examined the relationship between suPAR and diastolic parameters. Consistent with other studies (35,37) suPAR was significantly associated with diastolic function (E/E') after multivariate adjustment. This could be related to impaired coronary microcirculation and increased arterial stiffness seen in patients with elevated suPAR levels (37)(38)(39)(40).…”

Section: Discussionsupporting

confidence: 91%

Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients

Manshad

Ballout

Borgia

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundPlasma cardiac biomarkers have emerged as a cost-effective diagnostic tool aimed at early identification of cardiotoxicity. Soluble urokinase plasminogen activator receptor (suPAR) is a bone marrow cell derived signaling molecule that is associated with cardiovascular disease outcomes.ObjectivesWe investigated associations between suPAR and global longitudinal strain (GLS) as a marker of early myocardial impairment in lung cancer patients.MethodsWe retrospectively analyzed 52 patients with stage IV non-small cell lung cancer with normal left ventricular ejection fraction (LVEF >55%) and without known heart disease or end-stage renal disease (ESRD). We studied associations between cardiac biomarkers and echocardiographic measures of systolic and diastolic function. GLS was analyzed using 2D speckle-tracking echocardiography via vendor-independent software (TomTec).ResultsMedian plasma suPAR was 7.0 ng/mL (interquartile range: 5.4–9.0). Mean LVEF was 61.9 ± 8.3% and mean GLS was-19.3 ± 2.1%. Inter-observer reproducibility was excellent for GLS as determined by Intraclass Correlation Coefficient analysis, ICC = 0.81 (0.68–0.89). After multivariate analysis, suPAR was the only biomarker associated with GLS (p = 0.009). suPAR was also associated with diastolic parameters E velocity (p = 0.018), A velocity (p = 0.017), and E/E' ratio (p = 0.033). Interestingly, suPAR was not associated with LVEF (p = 0.916). In addition, suPAR and GLS were found to be age-independent predictors of all-cause mortality, though only GLS remained significant after multivariate adjustment.ConclusionsIn this cohort of stage IV non-small cell lung cancer patients with normal LVEF and without known heart disease or ESRD, suPAR was associated with GLS and diastolic impairment. suPAR is a readily available inexpensive biomarker; further research is required to evaluate the possible role of suPAR in screening for subclinical LV dysfunction in the high-risk oncological population.

show abstract

Section: Discussionsupporting

confidence: 91%

Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients

Manshad

Ballout

Borgia

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…However, while there is little data concerning high plasma suPAR levels in CHD, 47 to the author's knowledge, there is limited evidence that simultaneously analyzed and correlated plasma and salivary suPAR levels and hs‐CRP in patients with periodontitis and CHD to investigate suPAR as a marker of subclinical risk of endothelial dysfunction and CHD. At the same time, there is no considerable amount of evidence to show that augmented expression of salivary suPAR levels may reflect an increase of plasma suPAR and therefore hypothesize that the salivary suPAR may be a non‐invasive test that could investigate earlier endothelial dysfunction and CHD.…”

Section: Discussionmentioning

confidence: 99%

Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase‐type plasminogen activator receptor (suPAR) levels

Isola

Polizzi

Alibrandi

et al. 2020

Journal of Periodontology

View full text Add to dashboard Cite

Background Previous studies have demonstrated that a soluble urokinase‐type plasminogen activator receptor (suPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of coronary heart disease (CHD) and periodontitis. The aim of this study was to analyze the impact of gingival health, periodontitis, and CHD on suPAR levels in plasma and saliva and to evaluate suPAR as a biomarker of periodontitis and CHD. Methods Healthy controls (n = 33), patients with periodontitis (n = 31), CHD (n = 29), and a combination of periodontitis + CHD (n = 29) were enrolled in the present study. All patients were clinically and periodontally evaluated and regularly assessed for socioeconomic status, serum lipids, high‐sensitivity C‐reactive protein (hs‐CRP), and for plasma and salivary suPAR levels. Results Patients with periodontitis (P <.001) and with periodontitis + CHD (P <.001) presented higher median plasma and salivary suPAR levels compared with CHD and healthy controls. Moreover, univariate regression analysis demonstrated that hs‐CRP (P <.001) and periodontitis (P <.001) had a significant negative direct effect on both plasma and salivary suPAR levels. The multivariate regression analysis showed that periodontitis was the only significant predictor of plasma suPAR (P = .035) while hs‐CRP was the only significant predictor of salivary suPAR (P <.001). Conclusions The results of the present study demonstrated that patients with periodontitis and periodontitis + CHD presented higher suPAR levels in both plasma and saliva in comparison with healthy controls and CHD. Moreover, periodontitis and hs‐CRP were the only significant predictors of the augmented suPAR levels in plasma and saliva, respectively.

show abstract

“…14 Its soluble form has been associated with diastolic dysfunction in HFpEF patients. 15 leads to a phenotype of concentric hypertrophy. 16 It is hypothesized that the ratio between TNF-R1 and TNF-R2 is responsible for the type of hypertrophy that develops.…”

Section: Discussionmentioning

confidence: 99%

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment

Nauta

Hummel

Tromp

et al. 2019

European J of Heart Fail

View full text Add to dashboard Cite

Heart failure is traditionally classified by left ventricular ejection fraction (LVEF), rather than by left ventricular (LV) geometry, with guideline-recommended therapies in heart failure with reduced ejection fraction (HFrEF) but not heart failure with preserved ejection fraction (HFpEF). Most patients with HFrEF have eccentric LV hypertrophy, but some have concentric LV hypertrophy. We aimed to compare clinical characteristics, biomarker patterns, and response to treatment of patients with HFrEF and eccentric vs. concentric LV hypertrophy.

show abstract

Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction

Cited by 9 publications

References 48 publications

Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients

Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients

Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase‐type plasminogen activator receptor (suPAR) levels

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment

Contact Info

Product

Resources

About